Syndax Pharmaceuticals Inc
SNDX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001395937
In the last 90 days, Syndax Pharmaceuticals Inc insiders filed 0 open-market purchases and 1 sale; 242 institutions reported holding it in 13F filings for Q2 2026, worth $2.36B in total; no superinvestor holds it.
13F holders, Q3 2022
Institutional positions in Syndax Pharmaceuticals Inc as of Sep 30, 2022. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 139
- +18 vs. Q2 2022
- Shares held
- 59.9M
- +4.67M (+8.4%) vs. Q2 2022
- Total value
- $1.44B
- +$376.7M (+35.5%) vs. Q2 2022
- New holders
- 30
- 61 more added
- Sold out
- 12
- 27 more reduced
Compare with Q2 2022: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting SNDX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 242 | $2.36B |
| Q1 2026 | 247 | $2.32B |
| Q4 2025 | 230 | $2.10B |
| Q3 2025 | 227 | $1.56B |
| Q2 2025 | 217 | $952.6M |
| Q1 2025 | 219 | $1.24B |
| Q4 2024 | 216 | $1.30B |
| Q3 2024 | 210 | $1.71B |
| Q2 2024 | 196 | $1.79B |
| Q1 2024 | 189 | $2.15B |
| Q4 2023 | 177 | $1.92B |
| Q3 2023 | 175 | $1.03B |
| Q2 2023 | 166 | $1.48B |
| Q1 2023 | 163 | $1.54B |
| Q4 2022 | 160 | $1.82B |
| Q3 2022 | 139 | $1.44B |
| Q2 2022 | 121 | $1.06B |
| Q1 2022 | 136 | $948.4M |
| Q4 2021 | 132 | $1.15B |
| Q3 2021 | 123 | $938.0M |
| Q2 2021 | 115 | $861.9M |
| Q1 2021 | 130 | $1.08B |
Institutions, Q3 2022
Shares, value and share of portfolio for each institution holding Syndax Pharmaceuticals Inc; share changes are against Q2 2022.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Bank of America Corp | 302,128 | $7.26M | 0.00% | +226,494+299.5% | Added |
| Acuta Capital Partners, LLC | 324,614 | $7.80M | 3.47% | +119,611+58.3% | Added |
| Lord, Abbett & Co. LLC | 334,963 | $8.05M | 0.03% | +20,049+6.4% | Added |
| DAFNA Capital Management LLC | 355,487 | $8.54M | 2.30% | −15,500−4.2% | Reduced |
| Two Sigma Advisers, LP | 371,752 | $8.93M | 0.03% | +18,900+5.4% | Added |
| Charles Schwab Investment Management Inc | 385,121 | $9.26M | 0.00% | +28,216+7.9% | Added |
| Northern Trust Corp | 503,962 | $12.1M | 0.00% | +16,049+3.3% | Added |
| Sofinnova Investments, Inc. | 525,002 | $12.6M | 0.80% | +111,574+27.0% | Added |
| Citigroup Inc | 530,986 | $12.8M | 0.02% | +67,007+14.4% | Added |
| Goldman Sachs Group Inc | 568,081 | $13.7M | 0.00% | +21,842+4.0% | Added |
| Palo Alto Investors LP | 612,600 | $14.7M | 1.16% | 00.0% | Unchanged |
| JPMorgan Chase & Co | 616,251 | $14.8M | 0.00% | +21,949+3.7% | Added |
| Foresite Capital Management IV, LLC | 690,000 | $16.6M | 5.33% | +690,000 | New |
| Commodore Capital LP | 738,110 | $17.7M | 2.85% | +738,110 | New |
| Woodline Partners LP | 789,273 | $19.0M | 0.28% | +789,273 | New |
| Sphera Funds Management Ltd. | 822,696 | $19.8M | 3.50% | −316,633−27.8% | Reduced |
| HealthCor Management, L.P. | 859,240 | $20.6M | 2.58% | −64,160−6.9% | Reduced |
| T. Rowe Price Investment Management, Inc. | 923,226 | $22.2M | 0.02% | +923,226 | New |
| Geode Capital Management, LLC | 968,129 | $23.3M | 0.00% | +60,273+6.6% | Added |
| Aisling Capital Management LP | 1,025,000 | $24.6M | 16.36% | 00.0% | Unchanged |
| Paradigm Biocapital Advisors LP | 1,085,142 | $26.1M | 3.67% | +208,986+23.9% | Added |
| Dimensional Fund Advisors LP | 1,122,452 | $27.0M | 0.01% | +161,346+16.8% | Added |
| 683 Capital Management, LLC | 1,130,000 | $27.2M | 2.19% | −451,653−28.6% | Reduced |
| Eversept Partners, LP | 1,211,434 | $29.1M | 3.45% | +217,072+21.8% | Added |
| Adage Capital Partners GP, L.L.C. | 1,250,000 | $30.0M | 0.07% | +12,700+1.0% | Added |
| PFM Health Sciences, LP | 1,289,073 | $31.0M | 1.18% | +708,305+122.0% | Added |
| Citadel Advisors LLC | 1,366,771 | $32.8M | 0.04% | −362,281−21.0% | Reduced |
| Nantahala Capital Management, LLC | 1,375,428 | $33.1M | 3.24% | −1,287,659−48.4% | Reduced |
| Jennison Associates LLC | 1,649,795 | $39.6M | 0.04% | +1,649,795 | New |
| BVF Inc | 1,798,085 | $43.2M | 1.78% | −558,849−23.7% | Reduced |
| OrbiMed Advisors LLC | 2,006,500 | $48.2M | 0.96% | −316,800−13.6% | Reduced |
| Avoro Capital Advisors LLC | 2,222,222 | $53.4M | 0.99% | 00.0% | Unchanged |
| Kynam Capital Management, LP | 2,272,915 | $54.6M | 11.54% | −239,325−9.5% | Reduced |
| State Street Corp | 2,617,437 | $62.9M | 0.00% | +181,920+7.5% | Added |
| Vanguard Group Inc | 2,802,299 | $67.3M | 0.00% | +21,396+0.8% | Added |
| Frazier Life Sciences Management, L.P. | 3,412,838 | $82.0M | 6.31% | +217,435+6.8% | Added |
| BlackRock Inc. | 4,139,617 | $99.5M | 0.00% | +343,708+9.1% | Added |
| Wellington Management Group LLP | 4,387,440 | $105.4M | 0.02% | +1,180,574+36.8% | Added |
| Avidity Partners Management LP | 5,586,900 | $134.3M | 2.92% | +136,900+2.5% | Added |
| Deerfield Management Company, L.P. (Series C) | 0 | $0 | 0.00% | −1,111,111−100.0% | Sold out |
| Phoenix Holdings Ltd. | 0 | $0 | 0.00% | −525,856−100.0% | Sold out |
| Silverarc Capital Management, LLC | 0 | $0 | 0.00% | −107,852−100.0% | Sold out |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −94,474−100.0% | Sold out |
| Tekla Capital Management LLC | 0 | $0 | 0.00% | −56,480−100.0% | Sold out |
| Millennium Management LLC | 0 | $0 | 0.00% | −24,601−100.0% | Sold out |
| PEAK6 Investments LLC | 0 | $0 | 0.00% | −16,000−100.0% | Sold out |
| Principle Wealth Partners LLC | 0 | $0 | 0.00% | −14,000−100.0% | Sold out |
| Marshall Wace, LLP | 0 | $0 | 0.00% | −11,637−100.0% | Sold out |
| Gsa Capital Partners LLP | 0 | $0 | 0.00% | −11,542−100.0% | Sold out |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −288−100.0% | Sold out |
| Dark Forest Capital Management LP | 0 | $0 | 0.00% | −65−100.0% | Sold out |